Wegovy pill (oral semaglutide): evidence, safety and status

Q: Is the pill as effective as the injection?

No head-to-head trial of the pill against the injection was found. Cross-trial, the 13.6% loss at 64 weeks in OASIS 4 sits close to the 14.9% loss at 68 weeks with weekly 2.4 mg injections in STEP 1 [Human RCT, n=1,961] (Wilding 2021). The two trials enrolled different people at different times, so the numbers are not a direct comparison. Novo Nordisk describes the weight loss as "similar to that of injectable Wegovy 2.4 mg".

Q: How does it differ from orforglipron (Foundayo)?

Orforglipron, sold as Foundayo, is Eli Lilly's GLP-1 pill, approved by the FDA for weight management. Unlike semaglutide, it is a small molecule rather than a peptide (Wharton 2025, ATTAIN-1). In ATTAIN-1 its 36 mg dose produced −11.2% vs −2.1% on placebo at 72 weeks [Human RCT, n=3,127] (Wharton 2025, ATTAIN-1). Set beside OASIS 4's −13.6% vs −2.2%, this is a cross-trial comparison: the trials differ in length, population and design, and no head-to-head obesity trial of the two pills was found.

Q: Is the Wegovy pill as effective as the injection?

It appears broadly similar, but no head-to-head trial was found. In OASIS 4, the 25 mg pill produced 13.6% weight loss at 64 weeks; in STEP 1, weekly 2.4 mg injections produced 14.9% at 68 weeks (Wilding 2021). These are cross-trial numbers from different populations and should not be read as a direct comparison.

Q: What are the side effects of oral semaglutide?

The most common are gastrointestinal: nausea, diarrhea, constipation and vomiting. In OASIS 4, 74.0% on the tablet and 42.2% on placebo reported gastrointestinal events (Wharton 2025). The label also warns of pancreatitis, gallbladder disease and kidney injury from fluid loss, and carries a boxed warning on thyroid C-cell tumors seen in rodents.

Q: What are the disadvantages of oral semaglutide?

It is taken every day, on an empty stomach, with no food, drink or other oral medicines for at least 30 minutes afterward, according to the FDA label (FDA label). Gastrointestinal side effects are common, and levothyroxine exposure rose 33% when taken with semaglutide tablets, which matters for people on thyroid medicine.

Q: Is the Wegovy pill the same as Rybelsus?

Both are semaglutide tablets that rely on the absorption enhancer SNAC, but they are separate products. Rybelsus was approved by the FDA in 2019 for type 2 diabetes (Solis-Herrera 2024). Wegovy tablets were approved in 2025 for weight reduction and cardiovascular risk reduction, with a 25 mg maintenance dose and their own label.

The Wegovy pill is oral semaglutide 25 mg, a once-daily tablet form of the GLP-1 peptide drug in Wegovy injections. In the OASIS 4 trial (Human RCT, n=307), adults with obesity or overweight lost an average of 13.6% of body weight at 64 weeks, against 2.2% on placebo (Wharton 2025). The FDA approved it on 2025-12-22 for weight reduction and cardiovascular risk reduction, the first GLP-1 pill approved for weight management (Novo Nordisk, 2025). Its strongest evidence is an approved label backed by phase 3 trials; stomach upset is its most common side effect.

Item	Status
US FDA	Approved 2025-12-22 as Wegovy tablets (NDA 218316): weight reduction and maintenance, and lower risk of major cardiovascular events (FDA label). US launch 2026-01-05.
Compounding	Semaglutide shortage resolved 2025-02-21; 503A discretion ended 2025-04-22, 503B 2025-05-22 (FDA). FDA proposed excluding semaglutide from the 503B bulks list on 2026-04-30; not final (FDA).
WADA	Not prohibited on the 2026 List (USADA). The 2027 List (in force 2027-01-01) keeps it permitted and puts semaglutide in the Monitoring Program (USADA).
UK / EU	MHRA approved 2026-06-11; not on the NHS pending NICE (MHRA). EU approval announced July 2026 (Novo Nordisk).
Strongest evidence	Approved label; Human RCTs (OASIS 4, n=307, 25 mg)
Human trials	Obesity program: OASIS 1–4 completed, OASIS 5 recruiting (NCT07770841); OASIS 4 is NCT05564117
Next regulatory step	Novo Nordisk filed the 25 mg dose as an “Ozempic pill” for type 2 diabetes; FDA decision expected Q4 2026 (Novo Nordisk Q2 2026)
Last checked	2026-10-17

Strongest evidence: The Wegovy pill: Approved. US FDA: Approved 2025-12-22 as Wegovy tablets. WADA: Not prohibited on the 2026 List. Human trials: Obesity program. — Drawn from the status box above, last checked 2026-10-17.

Key points:

When participants kept taking the tablet as planned, OASIS 4 weight loss averaged 16.6%, and about one in three lost 20% or more (sponsor analysis).
Semaglutide is a peptide, so the tablet carries an absorption enhancer, SNAC, that lets it pass through the stomach wall.
The label requires an empty stomach and a 30-minute wait before food, drink or other oral medicines.
A 50 mg oral dose produced 15.1% weight loss in OASIS 1, but 50 mg is not an approved dose.
Oral semaglutide 14 mg did not slow early Alzheimer’s disease in two phase 3 trials (n=3,808).

Property	Value
Active ingredient	Semaglutide, a modified GLP-1 analogue peptide
Molecular formula	C187H291N45O59
Molecular weight	4114 g/mol
PubChem CID	56843331
Half-life	About 1 week (Granhall 2019)
Absorption enhancer	SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate)
Tablet strengths	1.5, 4, 9 and 25 mg
Class	GLP-1 receptor agonist

What is the Wegovy pill?

The Wegovy pill is the tablet version of Wegovy, the weight-management brand of semaglutide. Semaglutide was first given by mouth as Rybelsus, which the FDA approved in 2019 for type 2 diabetes; its tablet uses the absorption enhancer SNAC to help the peptide be absorbed in the stomach and to protect it from digestive enzymes (Solis-Herrera 2024). Novo Nordisk then tested higher oral doses for weight loss in the OASIS trials and filed the 25 mg tablet with the FDA; the application was received on 2025-02-28 (FDA approval letter). Approval followed on 2025-12-22, and the US launch on 2026-01-05 (Novo Nordisk Q2 2026). The tablet contains the same active ingredient as the weekly injection, but it is a separate product with its own strengths and label.

How does oral semaglutide work?

GLP-1 receptor activation: semaglutide mimics the gut hormone GLP-1 (glucagon-like peptide-1), which acts on appetite and blood sugar; in a trial of oral semaglutide 50 mg, food eaten at a free buffet fell 39.2 percentage points more than with placebo at week 20 [Human RCT, n=61] (Gabe 2024).
Absorption in the stomach: human and dog studies showed the tablet is absorbed in the stomach, close to the tablet surface, and only when co-formulated with SNAC, which buffers the area against digestive enzymes [Human and Animal] (Buckley 2018).
No opening of gut junctions: the same work found absorption passes through cells (transcellular), “without any evidence of effect on tight junctions” [Human and Animal] (Buckley 2018).
Long half-life: semaglutide’s half-life was about 1 week in healthy volunteers and people with type 2 diabetes, and the results supported once-daily oral dosing [Human, n=242 across two trials] (Granhall 2019).

Benefits of oral semaglutide: what the research shows

The main benefit shown for the Wegovy pill is weight loss: 13.6% at 64 weeks in OASIS 4, 11.4 percentage points more than placebo [Human RCT, n=307]. Physical function scores on a weight-related quality-of-life questionnaire also improved more than with placebo in the same trial. Semaglutide’s cardiovascular benefit comes from two outcome trials: injectable semaglutide in people without diabetes and oral semaglutide in people with type 2 diabetes.

Claim	Evidence level	Best study and result
Weight loss, 25 mg tablet	Human RCT; Approved label	Wharton 2025, n=307: −13.6% vs −2.2% at 64 weeks
Weight loss, 50 mg tablet	Human RCT (dose not approved)	Knop 2023, n=667: −15.1% vs −2.4%
Weight loss, East Asian adults	Human RCT (50 mg)	Kadowaki 2025, n=201: −14.3% vs −1.3%
Less food eaten	Human RCT (50 mg)	Gabe 2024, n=61: intake −39.2 points vs placebo
Fewer heart attacks, strokes, CV deaths (type 2 diabetes)	Human RCT (oral)	McGuire 2025, n=9,650: 12.0% vs 13.8%, HR 0.86
Fewer CV events (obesity, no diabetes)	Human RCT (injection); Approved label for tablets	Lincoff 2023, n=17,604: 6.5% vs 8.0%, HR 0.80
Slower early Alzheimer’s disease	Human RCT: not shown	evoke/evoke+, n=3,808, 14 mg: no superiority vs placebo

Weight loss

OASIS 4 randomized 205 adults to oral semaglutide 25 mg and 102 to placebo, all with lifestyle support; none had diabetes (Wharton 2025). The difference of −11.4 percentage points had a 95% confidence interval of −13.9 to −9.0 (P<0.001), and more people on the tablet reached each threshold of 5%, 10%, 15% and 20% loss [Human RCT]. The 13.6% figure is the trial’s primary estimate; Novo Nordisk’s 16.6% figure is the average “when treatment was adhered to” (Novo Nordisk, 2025). The trial was funded by Novo Nordisk.

Is the pill as effective as the injection?

No head-to-head trial of the pill against the injection was found. Cross-trial, the 13.6% loss at 64 weeks in OASIS 4 sits close to the 14.9% loss at 68 weeks with weekly 2.4 mg injections in STEP 1 [Human RCT, n=1,961] (Wilding 2021). The two trials enrolled different people at different times, so the numbers are not a direct comparison. Novo Nordisk describes the weight loss as “similar to that of injectable Wegovy 2.4 mg”.

Heart and blood-vessel outcomes

The tablet’s cardiovascular indication rests on SELECT, where weekly injectable semaglutide lowered the risk of major cardiovascular events (HR 0.80; 95% CI 0.72 to 0.90) in adults with heart disease and excess weight but no diabetes [Human RCT, n=17,604] (Lincoff 2023). Oral semaglutide has its own outcome trial: in SOUL, adults with type 2 diabetes and cardiovascular or kidney disease had major cardiovascular events in 12.0% of the semaglutide group and 13.8% of the placebo group over a mean 47.5 months (HR 0.86; 95% CI 0.77 to 0.96) [Human RCT, n=9,650] (McGuire 2025).

Alzheimer’s disease

Oral semaglutide 14 mg was tested in early Alzheimer’s disease in the evoke and evoke+ trials. Alzheimer’s-related biomarkers improved, but the trials “did not confirm superiority of semaglutide versus placebo” on the CDR-SB rating scale at week 104, and the one-year extension periods were stopped [Human RCT, n=3,808] (Novo Nordisk, 2025).

Human studies and trials

ClinicalTrials.gov lists five OASIS phase 3 trials of oral semaglutide for weight (searched 2026-10-17). Only OASIS 4 used the approved 25 mg dose; OASIS 1 to 3 went up to 50 mg.

Trial	Design and n	Status and result
OASIS 1 (NCT05035095)	Phase 3, 50 mg, n=667	Completed; −15.1% vs −2.4%
OASIS 2 (NCT05132088)	Phase 3, 50 mg, East Asian, n=201	Completed; −14.3% vs −1.3%
OASIS 3 (NCT05890976)	Phase 3, up to 50 mg, Chinese adults, n=200	Completed 2025-01-16; no journal paper found
OASIS 4 (NCT05564117)	Phase 3, 25 mg, n=307	Completed; −13.6% vs −2.2%
OASIS 5 (NCT07770841)	Phase 3, two oral doses, est. n=450	Recruiting; primary completion 2028-02-22
SOUL (NCT03914326)	Phase 3, type 2 diabetes, n=9,650	Completed; MACE HR 0.86

Doses used in studies

Route and amount	Species	Study
Oral, 25 mg once daily	Human, n=307	OASIS 4
Oral, 50 mg once daily	Human, n=667	OASIS 1
Oral, 50 mg once daily	Human, n=201	OASIS 2
Oral, 14 mg once daily	Human, n=3,808	evoke/evoke+

The approved label dose is 25 mg once daily, reached in monthly steps from 1.5 mg through 4 mg and 9 mg (FDA label). No established human dose exists outside approved labels.

Side effects and safety

Stomach and bowel complaints are the most common side effects. In OASIS 4, 74.0% of people on the tablet reported gastrointestinal adverse events, compared with 42.2% on placebo [Human RCT, n=307] (Wharton 2025). The MHRA lists nausea, diarrhoea, constipation and vomiting as the most common side effects (MHRA, 2026). Adverse reactions led 6.9% of people on the 25 mg tablet to stop permanently, against 5.9% on placebo [Approved label] (FDA label). At 50 mg in OASIS 1, 80% reported gastrointestinal events [Human RCT, n=667] (Knop 2023).

Label warnings and who should not use it

Boxed warning: semaglutide causes thyroid C-cell tumors in rodents; whether this applies to humans is unknown [Animal; Approved label]. Our page on GLP-1 drugs and cancer evidence covers the research behind this warning.
Contraindications: a personal or family history of medullary thyroid carcinoma or MEN 2, or a prior serious allergic reaction to semaglutide or the tablet’s ingredients.
Warnings and precautions: acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic eye complications, faster heart rate, and aspiration during general anesthesia or deep sedation.
Interactions: levothyroxine exposure rose 33% when taken with semaglutide tablets [Approved label].

All four points come from the FDA label for Wegovy tablets. In SOUL, serious adverse events were reported by 47.9% on oral semaglutide and 50.3% on placebo [Human RCT, n=9,650] (McGuire 2025).

Unapproved and compounded versions

The FDA warns that semaglutide salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, and that products labeled “for research purposes” are sold illegally for human use. By 2026-05-31 it had received 990 adverse-event reports linked to compounded semaglutide, and it documented dosing errors that led to hospital stays (FDA). Our page on what the “research use only” label means legally explains that label. Anyone who suspects a side effect from oral semaglutide or any other drug or product can report it to the FDA through MedWatch.

Disadvantages of oral semaglutide

The main practical drawback is the dosing condition. The label requires the tablet to be swallowed whole on an empty stomach in the morning with a small amount of water, with no food, drink or other oral medicines for at least 30 minutes (FDA label). The UK announcement describes fasting for at least 8 hours beforehand (MHRA, 2026). That condition matches how the tablet works: absorption happens in the stomach next to the tablet and depends on SNAC (Buckley 2018). The tablet is also a daily drug rather than a weekly one, and its gastrointestinal side-effect rate in OASIS 4 was high, at 74.0% (Wharton 2025).

How does it differ from orforglipron (Foundayo)?

Orforglipron, sold as Foundayo, is Eli Lilly’s GLP-1 pill, approved by the FDA for weight management. Unlike semaglutide, it is a small molecule rather than a peptide (Wharton 2025, ATTAIN-1). In ATTAIN-1 its 36 mg dose produced −11.2% vs −2.1% on placebo at 72 weeks [Human RCT, n=3,127] (Wharton 2025, ATTAIN-1). Set beside OASIS 4’s −13.6% vs −2.2%, this is a cross-trial comparison: the trials differ in length, population and design, and no head-to-head obesity trial of the two pills was found.

Legal and regulatory status

Jurisdiction	Status (checked 2026-10-17)
US FDA	Wegovy tablets approved 2025-12-22 (NDA 218316); Rybelsus (type 2 diabetes) approved 2019
US compounding	Shortage resolved 2025-02-21 (FDA); 503B exclusion proposed 2026-04-30, comments closed 2026-06-29, not final
WADA	Not prohibited (USADA); 2027 Monitoring Program from 2027-01-01
UK MHRA	Approved 2026-06-11; not on the NHS, pending NICE (MHRA)
EU	Approval announced July 2026 after a CHMP positive opinion in May 2026 (Novo Nordisk)

The FDA’s April 2026 proposal would exclude semaglutide from the list of bulk substances that 503B outsourcing facilities may compound with; the agency said it “did not identify a clinical need” and will decide after reviewing comments (FDA, 2026). Our explainer on FDA’s 503A Category 1 and Category 2 compounding lists covers how the bulk-substance lists work. For athletes, no therapeutic use exemption is needed because GLP-1 drugs are not prohibited, though WADA is monitoring their use; from 2027-01-01 semaglutide is monitored in and out of competition (USADA 2027 advisory).

Related peptides

CagriSema (cagrilintide + semaglutide): an investigational weekly injection pairing semaglutide with an amylin analogue.
Retatrutide FDA approval timeline: trial readouts and filing dates for Lilly’s investigational triple-receptor agonist.
Nisotirostide: an investigational Lilly peptide in the same GLP-1 and incretin category.

What users report

These are unverified self-reports posted on public forums and social media, not evidence; unlike most peptide discussions, many posters say they hold a prescription for the approved tablet. People who post about the Wegovy pill most often describe feeling full sooner and thinking less about food within the first weeks. A recurring complaint is the morning routine: waiting before coffee or breakfast, and fitting other morning medicines around the tablet. Nausea, burping, constipation and tiredness are the side effects mentioned most, often said to ease over time. Many posts compare the pill with the weekly injection; some prefer avoiding needles, while others say they lost less weight or found the daily routine harder to keep. Cost and insurance coverage come up frequently. Posts about orforglipron mainly argue over whether the lack of food restrictions matters more than differences in reported weight loss. Some posters also discuss stopping the drug and regaining weight.

Frequently asked questions

Is the Wegovy pill as effective as the injection?